Clinical Effectiveness of the ReHand App in Hand Rehabilitation After Stroke
ReHand. The First Tablet Solution for the Neurological Post-Stroke Rehabilitation of the Most Functional Body Segment, The Hand
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Older than 18 years.
- From 1 week to 6 months after stroke
- Ischemic or hemorrhagic stroke confirmation by computed tomography or magnetic resonance imaging.
- No previous impairments of the upper limb with the stroke affectation.
- Score above 20 on the Minimental State Examination test.
- Alertness and medical stability declared by the responsible neurologist and with ability to follow simple verbal commands
- Ability to move fingers, even partially.
Exclusion Criteria:
- Acute traumatic or orthopedic involvement of the limb in concern.
- Unstable medical condition (life expectancy less than 3 months, uncontrolled hypertension, unstable angina, recent myocardial infarction, etc.).
- Any medical condition that may confound interpretation of results or put the patient at risk (e.g. amputated finger, psychiatric illness, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tablet Application
An exercise program based on the current evidence will be provided through a tablet application (ReHand) along with the face-to-face conventional approach of each recruitment centres.
A follow-up of the use of the application will be carried out.
The treatment protocol will last 4 weeks, including daily exercise sessions of 30-60 minutes of duration at home though the application tablet.
|
Participants will receive a tablet app (ReHand) along with face-to-face physiotherapy sessions.
The ReHand app includes an exercise program based on current scientific evidence for improving funcional ability and dexterity of the hand with neurological affectation.
Those exercises are performed making controlled taps and movements while touching the touchscreen and guided by feedbacks.
Also, ReHand app includes a prescription and monitoring web-based system for professionals.
Along with this intervention, face-to-face physiotherapy sessions will be performed their respective centres.
|
|
Active Comparator: Conventional Treatment
Participants included in this group will receive the conventional treatment protocol usually prescribed on each recruitment centres.
Participants will be asked to perform an exercise program on paper during 4 weeks at home, along with face-to-face sessions.
|
Participants of this group will receive a home exercise program on paper and face-to-face physiotherapy sessions.
This intervention is the conventional approach usually delivered in their respective centres.
Those exercises were specifically developed for the rehabilitation of the hand with neurological affectation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Motor function of the upper limb using Fugl-Meyer Motor Assessment of the Upper Extremity (FMA-UE)
Time Frame: Change from Baseline Fugl-Meyer Motor Assessment of the Upper Extremity (FMA-UE) at 4 weeks.
|
A specific scale for the assessment of sensorimotor function of the upper limb after stroke.
It includes 33 items, which are rated from 0 to 2 (0 = cannot perform it, 1 = partially perform it, 2 = maximum performance).
Its overall score range from 0 to 66. Higher values correspond to greater motor ability.
|
Change from Baseline Fugl-Meyer Motor Assessment of the Upper Extremity (FMA-UE) at 4 weeks.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dexterity assessed using the Nine Hole Peg Test
Time Frame: Change from Baseline Nine Hole Peg Test at 4 weeks
|
Plastic instrument with a shallow round dish to contain pegs and nine holes on the opposite side.
It consist of measuring the time spent to place and remove all the pegs from the holes.
|
Change from Baseline Nine Hole Peg Test at 4 weeks
|
|
Grip strength assessed using a hydraulic grip dynamometer
Time Frame: Change from Baseline Grip Strength at 4 weeks
|
The Maximum power of the hand muscles used to firmly grasp an object by wrapping the fingers around it, pressing it against the palm, and using the thumb to apply counter-pressure, using a Hydraulic grip dynamometer
|
Change from Baseline Grip Strength at 4 weeks
|
|
Pinch strength assessed using a hydraulic pinch dynamometer
Time Frame: Change from Baseline Pinch Strength at 4 weeks
|
The maximun power of the pinch muscles, pressing the tip thumb against the tip index finger, using an Hydraulic pinch dynamometer.
|
Change from Baseline Pinch Strength at 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Pablo Rodriguez, University of Seville
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 825003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.